Mitoconix Bio

About Mitoconix Bio

Mitoconix Bio Ltd. is an Israeli-based biopharmaceutical company that operated from its establishment in August 2016 within the FutuRx incubator in Ness Ziona. The company was founded by Dr. Daria Mochly-Rosen, a Professor of Chemical and Systems Biology at Stanford University, based on scientific discoveries from her and her team. Dr. Mochly-Rosen's extensive background in translational medicine and her previous success founding Kai Pharmaceuticals, which was acquired by Amgen, provided a strong foundation for this new venture. Mitoconix Bio focused on developing treatments for neurodegenerative diseases by addressing mitochondrial dysfunction.

The company's core business was centered on pioneering a disease-modifying strategy to improve the health of mitochondria, the energy-generating organelles within cells whose dysfunction is linked to neurodegeneration. The business model revolved around the research and development of novel therapeutics, with the goal of advancing them through preclinical and clinical trials to eventually achieve regulatory approval and commercialization. A significant milestone was achieved in June 2017 when Mitoconix Bio secured $20 million in a Series A financing round. This funding was intended to advance its lead product through to clinical development and expand its pipeline. The company's operations appear to have ceased, as it is now listed as a deadpooled company.

Mitoconix Bio's lead product candidate was MTC-1203, a first-in-class selective inhibitor designed to prevent excessive mitochondrial division, a pathological process implicated in conditions like Huntington's and Parkinson's disease. The technology was exclusively licensed from Stanford University. MTC-1203 works by disrupting the interaction between specific proteins (DRP1 and Fis1) responsible for excessive mitochondrial fission, without affecting the normal, essential fission processes. This selective inhibition was designed to maintain neuronal health by improving mitochondrial functions, boosting ATP production, and reducing oxidative stress. Preclinical studies demonstrated efficacy, as MTC-1203 showed positive results in mouse models of Huntington's and Parkinson's diseases and in patient-derived cells for a range of neurodegenerative disorders.